Puma Biotechnology, Inc.
$7.37
▲
2.07%
2026-04-21 08:46:00
www.pumabiotechnology.com
NMS: PBYI
Explore Puma Biotechnology, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$374.96 M
Current Price
$7.37
52W High / Low
$7.9 / $2.75
Stock P/E
12.05
Book Value
$2.59
Dividend Yield
—
ROCE
27.62%
ROE
27.97%
Face Value
—
EPS
$0.61
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
179
Beta
1.18
Debt / Equity
21.9
Current Ratio
2
Quick Ratio
1.93
Forward P/E
11.97
Price / Sales
1.73
Enterprise Value
$326.84 M
EV / EBITDA
6.89
EV / Revenue
1.43
Rating
None
Target Price
$5
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Opus Genetics, Inc. | $5.54 | — | $394.17 M | — | -90.9% | -2.42% | $5.81 / $0.71 | $0.22 |
| 2. | Quince Therapeutics, Inc. | $1.27 | — | $22.33 M | — | -33.74% | -2.48% | $45.5 / $0.8 | $0.02 |
| 3. | Grace Therapeutics, Inc. | $4.59 | — | $71.03 M | — | -23.81% | -10.22% | $5.18 / $2 | $4.19 |
| 4. | Alector, Inc. | $2.71 | — | $298.53 M | — | -69.73% | -1.82% | $3.4 / $0.9 | $0.28 |
| 5. | Surrozen, Inc. | $32.25 | — | $362.52 M | — | -47.4% | 231.45% | $33.22 / $5.9 | $-19.21 |
| 6. | Telomir Pharmaceuticals, Inc. | $1.48 | — | $49.85 M | — | -178.22% | -3.18% | $3.1 / $1.05 | $0.17 |
| 7. | Armata Pharmaceuticals, Inc. | $12.5 | — | $421.28 M | — | -45.96% | 130.37% | $16.34 / $1.11 | $-6 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 75.45 M | 54.48 M | 52.44 M | 46.01 M | 59.08 M | — |
| Operating Profit | 17.11 M | 9.57 M | 6.64 M | 3.98 M | 13.37 M | — |
| Net Profit | 13.44 M | 8.84 M | 5.86 M | 2.97 M | 19.3 M | — |
| EPS in Rs | 0.26 | 0.17 | 0.12 | 0.06 | 0.38 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 228.37 M | 230.47 M | 235.64 M | 228.03 M |
| Operating Profit | 37.3 M | 30.97 M | 32.64 M | 30.72 M |
| Net Profit | 31.11 M | 30.28 M | 21.59 M | 0 M |
| EPS in Rs | 0.61 | 0.6 | 0.42 | 0 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 216.3 M | 213.33 M | 230.53 M | 222.06 M |
| Total Liabilities | 85.96 M | 121.21 M | 177.09 M | 200.45 M |
| Equity | 130.34 M | 92.12 M | 53.44 M | 21.61 M |
| Current Assets | 162.69 M | 147.66 M | 156.19 M | 134.28 M |
| Current Liabilities | 81.25 M | 96.11 M | 99.38 M | 77.48 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 41.8 M | 38.92 M | 27.01 M | -15.83 M |
| Investing CF | -36.19 M | -20.44 M | -19.12 M | 7.1 M |
| Financing CF | -45.2 M | -33.85 M | 0 M | 12.22 M |
| Free CF | 41.73 M | 38.86 M | 14.37 M | -22.83 M |
| Capex | -0.07 M | -0.06 M | -12.64 M | -7 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -2.19% | 3.34% | — | — |
| Earnings Growth % | 40.23% | 1079450% | — | — |
| Profit Margin % | 13.14% | 9.16% | 0% | — |
| Operating Margin % | 13.44% | 13.85% | 13.47% | — |
| Gross Margin % | 72.06% | 73.4% | 75.84% | — |
| EBITDA Margin % | 20.86% | 20.17% | 9.6% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.